Coronavirus (COVID-19) Updates

AmerisourceBergen and our global pharmaceutical healthcare businesses are monitoring the ongoing spread of the novel COVID-19 coronavirus.

As an active participant in the global pharmaceutical supply chain, we’re engaged with government and healthcare officials as these agencies and experts closely monitor the spread of COVID-19. We have business continuity plans that include our global workforce and our teams are in daily communications with manufacturers, monitoring inventory levels and customer purchasing behavior for any potential impact to the product supply chain.

We will continue to be highly engaged as the situation evolves on a day-to-day basis and will post updates here for our customers. 

Update on the Distribution of Veklury® (Remdesivir) from Gilead Sciences

Effective October 1, 2020, Veklury (remdesivir) will no longer be allocated by the U.S. Department of Health and Human Services (HHS), the Office of the Assistant Secretary for Preparedness and Response (ASPR) and State Departments of Health. This change is possible given that there is now sufficient supply of Veklury (remdesivir) to meet demand, even if a surge of COVID-19 cases occurs.

Starting October 1, 2020, hospitals can submit orders for Veklury (remdesivir) directly to AmerisourceBergen for the treatment of hospitalized COVID-19 patients. With this change, AmerisourceBergen, through its specialty distribution capabilities, will remain the sole U.S. distributor of Veklury (remdesivir) through the end of this year.  It is important to note that orders should be placed on an as needed basis to treat current patients in accordance with EUA documentation for Veklury (remdesivir).

For further information on the EUA remdesivir,  please see HHS’ October 1, 2020 announcement available at
Retail and specialty pharmacies are not eligible to purchase Veklury (remdesivir).

  • For additional information regarding purchasing or how to access Veklury (remdesivir), please email, or call 1-800-746-6273 or reach out directly to your AmerisourceBergen representative.
  • For information on clinical trials that are testing the use of remdesivir in COVID-19, please visit
  • For additional medical information about Veklury (remdesivir), please visit or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.

We will update this message if/when additional information becomes available.